PHPSXETF / FundPHARMACEUTICALS ULTRASECTOR PROFUND
Verdicts genuinely change. Free email alert the moment PHPSX's does — no target price to set, unlike a price alert.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
PHARMACEUTICALS ULTRASECTOR PROFUND · ProFunds
74 holdings
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 102% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 33.41% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 54% turns out to be. Matching more holdings can only raise this share, never lower it.
74 holdings, 48 matched (47% of weight). Portfolio as of 2026-07-31, filed 2026-09-23. Source: SEC Form N-PORT.
8.10% of this portfolio’s income is non-permissible — weighted across holdings, computed over 44% of portfolio weight (43 of 74 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
All holdings (74)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| N/A | UNSCREENED | 8.20% | no in-house ratios for this holding |
| N/A | UNSCREENED | 6.31% | no in-house ratios for this holding |
| N/A | UNSCREENED | 5.05% | no in-house ratios for this holding |
| N/A | UNSCREENED | 5.05% | no in-house ratios for this holding |
| N/A | UNSCREENED | 3.95% | no in-house ratios for this holding |
| CRINETICS PHARMACEUTICALS INC | UNSCREENED | 2.60% | no in-house ratios for this holding |
| MBX BIOSCIENCES INC | UNSCREENED | 2.28% | no in-house ratios for this holding |
| ATAI ATAIBECKLEY INC | NON_COMPLIANT | 2.03% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| DEFINIUM THERAPEUTICS INC | UNSCREENED | 2.00% | no in-house ratios for this holding |
| AMYLYX PHARMACEUTICALS INC | UNSCREENED | 1.62% | no in-house ratios for this holding |
| ENLIVEN THERAPEUTICS INC | UNSCREENED | 1.59% | no in-house ratios for this holding |
| CORT CORCEPT THERAPEUTICS INC | COMPLIANT | 1.57% | AAOIFI0.1% Usmani0.9% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.9% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| ALUMIS INC | UNSCREENED | 1.51% | no in-house ratios for this holding |
| N/A | UNSCREENED | 1.49% | no in-house ratios for this holding |
| NUVB NUVATION BIO INC | NON_COMPLIANT | 1.48% | AAOIFI21.7% Usmani38.6% Dow Jones Islamic20.6% S&P Shariah25.7% MSCI Islamic38.6% MSCI Islamic M-Series25.7% FTSE Shariah36.7% |
| TREVI THERAPEUTICS INC | UNSCREENED | 1.46% | no in-house ratios for this holding |
| LQDA LIQUIDIA CORP | COMPLIANT | 1.38% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NKTR NEKTAR THERAPEUTICS | NON_COMPLIANT | 1.33% | AAOIFI6.0% Usmani7.1% Dow Jones Islamic6.7% S&P Shariah9.2% MSCI Islamic7.1% MSCI Islamic M-Series9.2% FTSE Shariah0.0% |
| AMRX AMNEAL PHARMACEUTICALS INC | NON_COMPLIANT | 1.28% | AAOIFI39.5% Usmani57.1% Dow Jones Islamic77.5% S&P Shariah96.5% MSCI Islamic55.8% MSCI Islamic M-Series96.5% FTSE Shariah55.8% |
| BMY BRISTOL-MYERS SQUIBB COMPANY | NON_COMPLIANT | 1.26% | AAOIFI37.6% Usmani50.2% Dow Jones Islamic41.5% S&P Shariah44.1% MSCI Islamic50.2% MSCI Islamic M-Series44.1% FTSE Shariah48.0% |
| EDGEWISE THERAPEUTICS INC | UNSCREENED | 1.25% | no in-house ratios for this holding |
| OMEROS CORP | UNSCREENED | 1.24% | no in-house ratios for this holding |
| LGND LIGAND PHARMACEUTICALS INC | COMPLIANT | 1.24% | AAOIFI19.8% Usmani51.6% Dow Jones Islamic30.9% S&P Shariah38.5% MSCI Islamic51.6% MSCI Islamic M-Series38.5% FTSE Shariah50.4% |
| ELAN ELANCO ANIMAL HEALTH INC | NON_COMPLIANT | 1.23% | AAOIFI26.7% Usmani26.4% Dow Jones Islamic37.4% S&P Shariah40.5% MSCI Islamic26.4% MSCI Islamic M-Series40.5% FTSE Shariah26.4% |
| VERADERMICS INC | UNSCREENED | 1.21% | no in-house ratios for this holding |
| PCRX PACIRA BIOSCIENCES INC | UNRATED | 1.21% | AAOIFI23.3% Usmani28.3% Dow Jones Islamic32.3% S&P Shariah31.3% MSCI Islamic28.3% MSCI Islamic M-Series31.3% FTSE Shariah24.4% |
| VTRS VIATRIS INC | NON_COMPLIANT | 1.19% | AAOIFI62.1% Usmani39.2% Dow Jones Islamic94.1% S&P Shariah99.0% MSCI Islamic39.2% MSCI Islamic M-Series99.0% FTSE Shariah38.4% |
| JAZZ JAZZ PHARMACEUTICALS PLC | NON_COMPLIANT | 1.18% | AAOIFI36.6% Usmani46.9% Dow Jones Islamic54.5% S&P Shariah60.7% MSCI Islamic46.9% MSCI Islamic M-Series60.7% FTSE Shariah46.4% |
| ETON ETON PHARMACEUTICALS INC | COMPLIANT | 1.17% | AAOIFI1.3% Usmani15.5% Dow Jones Islamic3.6% S&P Shariah5.0% MSCI Islamic15.5% MSCI Islamic M-Series5.0% FTSE Shariah14.7% |
| MAZE MAZE THERAPEUTICS INC | COMPLIANT | 1.17% | AAOIFI3.3% Usmani11.7% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic11.7% MSCI Islamic M-Seriesfail FTSE Shariah7.6% |
| MRK MERCK & COMPANY INC | COMPLIANT | 1.17% | AAOIFI15.2% Usmani40.5% Dow Jones Islamic21.0% S&P Shariah20.4% MSCI Islamic40.5% MSCI Islamic M-Series20.4% FTSE Shariah40.5% |
| HROW HARROW INC | COMPLIANT | 1.16% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| JNJ JOHNSON & JOHNSON | COMPLIANT | 1.15% | AAOIFI6.6% Usmani22.6% Dow Jones Islamic9.3% S&P Shariah10.2% MSCI Islamic22.6% MSCI Islamic M-Series10.2% FTSE Shariah22.6% |
| RPRX ROYALTY PHARMA PLC | NON_COMPLIANT | 1.15% | AAOIFI21.8% Usmani44.1% Dow Jones Islamic53.0% S&P Shariah60.4% MSCI Islamic44.1% MSCI Islamic M-Series60.4% FTSE Shariah44.1% |
| INDIVIOR PHARMACEUTICALS INC | UNSCREENED | 1.12% | no in-house ratios for this holding |
| PBH PRESTIGE CONSUMER HEALTHCARE INC | NON_COMPLIANT | 1.09% | AAOIFI92.5% Usmani45.2% Dow Jones Islamic66.2% S&P Shariah65.0% MSCI Islamic44.8% MSCI Islamic M-Series65.0% FTSE Shariah44.3% |
| COLL COLLEGIUM PHARMACEUTICAL INC | NON_COMPLIANT | 1.09% | AAOIFI30.8% Usmani11.7% Dow Jones Islamic22.9% S&P Shariah22.6% MSCI Islamic11.7% MSCI Islamic M-Series22.6% FTSE Shariah11.4% |
| LLY ELI LILLY & COMPANY | COMPLIANT | 1.08% | AAOIFI3.7% Usmani33.4% Dow Jones Islamic5.6% S&P Shariah5.9% MSCI Islamic33.4% MSCI Islamic M-Series5.9% FTSE Shariah33.4% |
| OGN ORGANON & COMPANY | NON_COMPLIANT | 1.08% | AAOIFI234.3% Usmani63.8% Dow Jones Islamic292.0% S&P Shariah251.6% MSCI Islamic63.8% MSCI Islamic M-Series251.6% FTSE Shariah63.8% |
| EYPT EYEPOINT INC | NON_COMPLIANT | 1.06% | AAOIFIfail Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| HRMY HARMONY BIOSCIENCES HOLDINGS INC | NON_COMPLIANT | 1.06% | AAOIFI8.0% Usmani10.5% Dow Jones Islamic7.9% S&P Shariah8.0% MSCI Islamic10.5% MSCI Islamic M-Series8.0% FTSE Shariah10.1% |
| SUPERNUS PHARMACEUTICALS INC | UNSCREENED | 1.06% | no in-house ratios for this holding |
| PFE PFIZER INC | NON_COMPLIANT | 1.05% | AAOIFI38.6% Usmani30.6% Dow Jones Islamic45.7% S&P Shariah45.9% MSCI Islamic30.6% MSCI Islamic M-Series45.9% FTSE Shariah30.6% |
| WVE WAVE LIFE SCIENCES LTD | NON_COMPLIANT | 1.04% | AAOIFI6.1% Usmani8.5% Dow Jones Islamic3.0% S&P Shariah3.5% MSCI Islamic8.5% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| PAHC PHIBRO ANIMAL HEALTH CORP | NON_COMPLIANT | 1.04% | AAOIFI46.9% Usmani43.9% Dow Jones Islamic48.5% S&P Shariah59.2% MSCI Islamic43.9% MSCI Islamic M-Series59.2% FTSE Shariah40.3% |
| ANIP ANI PHARMACEUTICALS INC | NON_COMPLIANT | 1.04% | AAOIFI18.3% Usmani19.0% Dow Jones Islamic16.5% S&P Shariah17.6% MSCI Islamic19.0% MSCI Islamic M-Series17.6% FTSE Shariah19.0% |
| TARS TARSUS PHARMACEUTICALS INC | COMPLIANT | 1.03% | AAOIFI2.3% Usmani17.7% Dow Jones Islamic3.5% S&P Shariah4.3% MSCI Islamic17.7% MSCI Islamic M-Series4.3% FTSE Shariah14.4% |
| ZTS ZOETIS INC | NON_COMPLIANT | 1.02% | AAOIFI28.0% Usmani61.2% Dow Jones Islamic16.9% S&P Shariah14.7% MSCI Islamic61.2% MSCI Islamic M-Series14.7% FTSE Shariah60.0% |
| OCUL OCULAR THERAPEUTIX INC | NON_COMPLIANT | 1.00% | AAOIFI0.5% Usmani1.1% Dow Jones Islamic0.4% S&P Shariah0.4% MSCI Islamic1.1% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| XERS XERIS BIOPHARMA HOLDINGS INC | COMPLIANT | 1.00% | AAOIFI14.8% Usmani68.5% Dow Jones Islamic26.2% S&P Shariah33.9% MSCI Islamic68.5% MSCI Islamic M-Series33.9% FTSE Shariah59.9% |
| RAPPORT THERAPEUTICS INC | UNSCREENED | 0.99% | no in-house ratios for this holding |
| INVA INNOVIVA INC | NON_COMPLIANT | 0.98% | AAOIFI20.5% Usmani17.5% Dow Jones Islamic19.4% S&P Shariah21.1% MSCI Islamic17.5% MSCI Islamic M-Series21.1% FTSE Shariah16.8% |
| PRGO PERRIGO COMPANY PLC | NON_COMPLIANT | 0.97% | AAOIFI157.9% Usmani46.3% Dow Jones Islamic142.6% S&P Shariah124.5% MSCI Islamic46.1% MSCI Islamic M-Series124.5% FTSE Shariah44.0% |
| AXSM AXSOME THERAPEUTICS INC | COMPLIANT | 0.95% | AAOIFI2.9% Usmani27.1% Dow Jones Islamic2.8% S&P Shariah3.3% MSCI Islamic25.3% MSCI Islamic M-Series3.3% FTSE Shariah22.7% |
| AMPH AMPHASTAR PHARMACEUTICALS INC | NON_COMPLIANT | 0.87% | AAOIFI55.2% Usmani40.4% Dow Jones Islamic57.2% S&P Shariah43.9% MSCI Islamic40.4% MSCI Islamic M-Series43.9% FTSE Shariah35.8% |
| ARVN ARVINAS INC | NON_COMPLIANT | 0.85% | AAOIFI1.7% Usmani1.3% Dow Jones Islamic1.0% S&P Shariah0.6% MSCI Islamic1.3% MSCI Islamic M-Series0.6% FTSE Shariah0.1% |
| ALTO NEUROSCIENCE INC | UNSCREENED | 0.84% | no in-house ratios for this holding |
| SEPN SEPTERNA INC | NON_COMPLIANT | 0.71% | AAOIFI1.2% Usmani3.6% Dow Jones Islamic2.1% S&P Shariahfail MSCI Islamic3.6% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| LBRX LB PHARMACEUTICALS INC | NON_COMPLIANT | 0.69% | AAOIFI0.4% Usmani1.1% Dow Jones Islamic— S&P Shariah— MSCI Islamic1.1% MSCI Islamic M-Series— FTSE Shariah0.0% |
| CRMD CORMEDIX INC | NON_COMPLIANT | 0.68% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| THERAVANCE BIOPHARMA INC | UNSCREENED | 0.67% | no in-house ratios for this holding |
| ACRS ACLARIS THERAPEUTICS INC | NON_COMPLIANT | 0.62% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.6% MSCI Islamic0.8% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| PHAT PHATHOM PHARMACEUTICALS INC | NON_COMPLIANT | 0.60% | AAOIFI37.6% Usmani48.7% Dow Jones Islamic23.5% S&P Shariah24.1% MSCI Islamic48.7% MSCI Islamic M-Series24.1% FTSE Shariah48.0% |
| N/A | UNSCREENED | 0.58% | no in-house ratios for this holding |
| ZVRA ZEVRA THERAPEUTICS INC | NON_COMPLIANT | 0.58% | AAOIFI0.2% Usmani0.4% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.4% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| RLMD RELMADA THERAPEUTICS INC | NON_COMPLIANT | 0.57% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| AQST AQUESTIVE THERAPEUTICS INC | COMPLIANT | 0.48% | AAOIFI12.8% Usmani52.8% Dow Jones Islamic13.5% S&P Shariah15.5% MSCI Islamic52.8% MSCI Islamic M-Series15.5% FTSE Shariah46.1% |
| FULC FULCRUM THERAPEUTICS INC | NON_COMPLIANT | 0.47% | AAOIFI2.4% Usmani2.2% Dow Jones Islamic1.9% S&P Shariah1.8% MSCI Islamic2.2% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| LXRX LEXICON PHARMACEUTICALS INC | NON_COMPLIANT | 0.42% | AAOIFI7.5% Usmani24.6% Dow Jones Islamic11.1% S&P Shariah11.4% MSCI Islamic24.6% MSCI Islamic M-Series11.4% FTSE Shariah21.4% |
| BIOA BIOAGE LABS INC | NON_COMPLIANT | 0.39% | AAOIFI1.1% Usmani0.7% Dow Jones Islamic0.5% S&P Shariah— MSCI Islamic0.7% MSCI Islamic M-Series— FTSE Shariah0.0% |
| EOLS EVOLUS INC | NON_COMPLIANT | 0.31% | AAOIFI37.7% Usmani58.3% Dow Jones Islamic31.2% S&P Shariah26.9% MSCI Islamic58.3% MSCI Islamic M-Series26.9% FTSE Shariah55.3% |
| N/A | UNSCREENED | 0.24% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.03% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 14 points of portfolio weight — 19.0% of it passes S&P Shariah, 4.5% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 18.2% ratios fail on 31.0% 52.3% not rated under AAOIFI
ratios pass on 6.8% ratios fail on 41.5% 53.3% not rated under Usmani
ratios pass on 18.5% ratios fail on 29.5% 53.5% not rated under Dow Jones Islamic
ratios pass on 19.0% ratios fail on 28.7% 53.9% not rated under S&P Shariah
ratios pass on 4.5% ratios fail on 43.7% 53.3% not rated under MSCI Islamic
ratios pass on 17.5% ratios fail on 30.1% 53.9% not rated under MSCI Islamic M-Series
ratios pass on 6.8% ratios fail on 41.5% 53.3% not rated under FTSE Shariah
49 of 74 listed holdings carry our own per-methodology verdicts (49% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 47 (47% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| ATAI ATAIBECKLEY INC | 2.03% |
| NUVB NUVATION BIO INC | 1.48% |
| NKTR NEKTAR THERAPEUTICS | 1.33% |
| AMRX AMNEAL PHARMACEUTICALS INC | 1.28% |
| BMY BRISTOL-MYERS SQUIBB COMPANY | 1.26% |
| ELAN ELANCO ANIMAL HEALTH INC | 1.23% |
| VTRS VIATRIS INC | 1.19% |
| JAZZ JAZZ PHARMACEUTICALS PLC | 1.18% |
| RPRX ROYALTY PHARMA PLC | 1.15% |
| PBH PRESTIGE CONSUMER HEALTHCARE INC | 1.09% |
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
PHARMACEUTICALS ULTRASECTOR PROFUND (PHPSX) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Screened on its holdings, not its name
HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A holding it cannot cover far enough is reported as unrated rather than counted as a pass.
| Holding | Weight | Verdict |
|---|---|---|
| N/Anot matched to a ticker | 8.20% | Not screened |
| N/Anot matched to a ticker | 6.31% | Not screened |
| N/Anot matched to a ticker | 5.05% | Not screened |
| N/Anot matched to a ticker | 5.05% | Not screened |
| N/Anot matched to a ticker | 3.95% | Not screened |
| CRINETICS PHARMACEUTICALS INCnot matched to a ticker | 2.60% | Not screened |
| MBX BIOSCIENCES INCnot matched to a ticker | 2.28% | Not screened |
| ATAIATAIBECKLEY INC | 2.03% | Non-compliant |
| DEFINIUM THERAPEUTICS INCnot matched to a ticker | 2.00% | Not screened |
| AMYLYX PHARMACEUTICALS INCnot matched to a ticker | 1.62% | Not screened |
Top 10 of 74 holdings, 39.1% of the fund by weight. Every holding is screened, not only these.
What holds the number back
The positions keeping this fund short of 100% compliant by weight.
- N/Anot screened8.20%
- N/Anot screened6.31%
- N/Anot screened5.05%
- N/Anot screened5.05%
- N/Anot screened3.95%
- CRINETICS PHARMACEUTICALS INCnot screened2.60%
What changed, and when
Verdict history for PHPSX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for PHPSX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
This fund prices once a day, so its bars carry no intraday high or low — floor-trader pivots are not defined for it.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.80 | NEUTRAL |
| Stochastic %K (14) | 9.68 | BUY |
| CCI (20) | -85.10 | NEUTRAL |
| Williams %R (14) | -90.32 | BUY |
| MACD (12,26,9) | -0.13 | SELL |
| ROC (10) | 1.44 | BUY |
| Momentum (10) | 0.46 | BUY |
| EMA (10) | 33.80 | SELL |
| SMA (10) | 34.50 | SELL |
| EMA (20) | 33.85 | SELL |
| SMA (20) | 33.79 | SELL |
| EMA (30) | 33.94 | SELL |
| SMA (30) | 33.39 | SELL |
| EMA (50) | 34.29 | SELL |
| SMA (50) | 33.95 | SELL |
| EMA (100) | 34.36 | SELL |
| SMA (100) | 36.08 | SELL |
| EMA (200) | 32.27 | BUY |
| SMA (200) | 32.62 | SELL |
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.